DNTH vs. TNGX, ZNTL, ARCT, EOLS, LBPH, ALXO, PLRX, IRON, PRAX, and SPRY
Should you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Tango Therapeutics (TNGX), Zentalis Pharmaceuticals (ZNTL), Arcturus Therapeutics (ARCT), Evolus (EOLS), Longboard Pharmaceuticals (LBPH), ALX Oncology (ALXO), Pliant Therapeutics (PLRX), Disc Medicine (IRON), Praxis Precision Medicines (PRAX), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical preparations" industry.
Tango Therapeutics (NASDAQ:TNGX) and Dianthus Therapeutics (NASDAQ:DNTH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.
Dianthus Therapeutics has lower revenue, but higher earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Tango Therapeutics has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500.
In the previous week, Dianthus Therapeutics had 6 more articles in the media than Tango Therapeutics. MarketBeat recorded 16 mentions for Dianthus Therapeutics and 10 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.71 beat Dianthus Therapeutics' score of -0.36 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.
Tango Therapeutics presently has a consensus target price of $17.25, indicating a potential upside of 129.39%. Dianthus Therapeutics has a consensus target price of $42.83, indicating a potential upside of 67.12%. Given Dianthus Therapeutics' higher probable upside, research analysts plainly believe Tango Therapeutics is more favorable than Dianthus Therapeutics.
Dianthus Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -299.88%. Tango Therapeutics' return on equity of -20.82% beat Dianthus Therapeutics' return on equity.
Tango Therapeutics received 2 more outperform votes than Dianthus Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Dianthus Therapeutics an outperform vote while only 56.52% of users gave Tango Therapeutics an outperform vote.
79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 6.2% of Tango Therapeutics shares are held by insiders. Comparatively, 16.6% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Dianthus Therapeutics beats Tango Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Dianthus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dianthus Therapeutics Competitors List
Related Companies and Tools
